These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16966063)

  • 1. [Nephrotoxicity of sirolimus: experimental and clinical data].
    Pallet N; Thervet E; Legendre C; Anglicheau D
    Nephrol Ther; 2006 Sep; 2(4):183-90. PubMed ID: 16966063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus: its role in nephrology.
    Lee VW; Chapman JR
    Nephrology (Carlton); 2005 Dec; 10(6):606-14. PubMed ID: 16354246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
    Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of side effects of sirolimus therapy.
    Stallone G; Infante B; Grandaliano G; Gesualdo L
    Transplantation; 2009 Apr; 87(8 Suppl):S23-6. PubMed ID: 19384183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J; Ríos M G; Vignolo A P; Pinochet V C; Schultz M; Humeres A R; Delucchi A; Rius A M; Hepp K J
    Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of symposium. Sirolimus in kidney transplantation.
    Schena FP
    Transplantation; 2009 Apr; 87(8 Suppl):S30-3. PubMed ID: 19384185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of sirolimus in renal transplantation: an update.
    Chueh SC; Kahan BD
    Transpl Int; 2005 Mar; 18(3):261-77. PubMed ID: 15730485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitors in hematologic malignancies.
    Dancey JE
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-based therapy for kidney transplantation from expanded criteria donors.
    Rigotti P; Kahan BD
    Transplantation; 2009 Apr; 87(8 Suppl):S11-3. PubMed ID: 19384180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus--challenging current perspectives.
    Buhaescu I; Izzedine H; Covic A
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J; Arellano EM; Carreras J; Campos B; Vodenik B; Bañón-Maneus E; Ramírez-Bajo MJ; Moya-Rull D; Solé-González A; Hernández A; Revuelta I; Quintana LF; Howat WJ; Campistol JM; Diekmann F
    Transplantation; 2009 Sep; 88(5):646-52. PubMed ID: 19741461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ; Tian YC; Chen YC; Lai BC; Fang JT; Yang CW; Wu MS
    Ren Fail; 2008; 30(3):303-6. PubMed ID: 18350450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.
    Paoletti E; Cannella G
    Transplant Proc; 2009; 41(6 Suppl):S3-5. PubMed ID: 19651293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible mechanism by which rapamycin increases cyclosporine nephrotoxicity.
    Cheng CH; Chang HR; Chiang CW; Shu KH; Chou MC
    Transplant Proc; 2008 Sep; 40(7):2373-5. PubMed ID: 18790238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.